Hyporesponsiveness to erythropoietin: Overview, 1996

Peritoneal Dialysis International

Volumn 16, Issue 4, 1996, Pages 417-420

  Nissenson, A R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; HEMATOCRIT; HUMAN; INFLAMMATION; IRON DEFICIENCY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY;

EID: 0029810367     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601600417     Document Type: Short Survey

References (31)

1. Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994; 88:34-43.
2. Krantz SB. Erythropoietin. Blood 1991; 77:419-34.
3. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW. USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol 1989; 76:160-5.
4. Van Wyck DB, Stivelman JC, Ruiz J, et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35:712-6.
5. Tarng DC, Chen TW, Huang TP. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 1995; 15:230-7.
6. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy.Nephrol Dial Transplant 1995; 10:2070-6.
7. Ureña P, Eckardt KU, Sarfati E, et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectormy.Nephron 1991; 59:384-93.
8. Washio M, Iseki K, Onayoma K,et al. Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic hemodialysis patients. Nephrol Dial Transplant 1992; 7:121-4.
9. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia.N Engl J Med 1993; 328:171-5.
10. Zachee P, Vanuystel J, Daelemans R, Lins RL. Erythropoietin needs after parathyroidectomy in haemodialysis patients (Abstract). Nephrol Dial Transplant 1994; 9:1039.
11. Hernandez E, Sanchez R, Praga M, et al. Influence of intravenous calcitrol on the response to erythropoietin in haemodialysis patients with hyperparathyroidism (Abstract). Nephrol Dial Transplant 1994; 9:1031.
12. Drüeke TB. Adynamic bone disease, anaemia, resistance to erythropoietin and iron-aluminium interaction. Neprhol Dial Transplant 1993; 8(Suppl 1):12-6.
13. Cannata JB, Lopez JBD. Insights into the complex aluminium and iron relationship. Nephrol Dial Transplant 1991; 6:605-7.
14. Bia MJ, Cooper K, Sehnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989; 36:852-8.
15. Douglas SW, Adamson JW. The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 1975; 45:55-65.
16. Johnson RA, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor- (TNF-): reversal with exogenous erythropoietin.Exp Hematol 1990; 18:109-15.
17. Clibon U, Bonewald L, Caro J, Roodman GD. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. Exp Hematol 1990; 18:438-41.
18. Macdougall IC, Allen DA, Cavill I, Baker LRI, Raine AEG. Poor response to erythropoietin in inflammatory conditions may be mediated by interleukin-6 (Abstract). Nephrol Dial Transplant 1994; 9:1033.
19. Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.Blood 1993; 82:2010-16.
20. Romero R, Novoa D, Perez-Freiria A, et al. Responsiveness to erythropoietin and intrinsic inflammatory status in haemodialysis (Letter).Nephrol Dial Transplant 1994; 9:1696-7.
21. Gaston R, Julian B, Curtis J. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994; 24:1-11.
22. Kamper A, Nielsen O. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990; 50:611-8.
23. Dhont AW, Vanholder RC, Ringoir SMG. Angiotensinconverting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients.Nephrol Dial Transplant 1995; 10:2107-9.
24. Walter J. Does captopril decrease the effect of recombinant erythropoietin in haemodialysis patients? (Abstract). Nephrol Dial Transplant 1993; 8:1428.
25. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334:420-5.
26. Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5:1517-29.
27. 12 deficiency. Am J Nephrol 1992; 12:188-91.
28. Tomson CRV, Edmunds ME, Chambers K,et al. Effects of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992; 7:817-21.
29. Ng YY, Chow MP, Lyou JY, Hu HY, et al. Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers. Am J Kidney Dis 1993; 21:213-6.
30. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of the response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-63.
31. Sungur C, Arik N, Yasavul U, Turgan C, Caglar S. Decreased response to human recombinant erythropoietin therapy in pregnancy. Am J Nephrol 1992; 12: 90.